Literature DB >> 12213729

Different incidence and pattern of p15INK4b and p16INK4a promoter region hypermethylation in Hodgkin's and CD30-Positive non-Hodgkin's lymphomas.

María J García1, Beatriz Martínez-Delgado, Arancha Cebrian, Angel Martínez, Javier Benítez, Carmen Rivas.   

Abstract

The p16INK4a and p15INK4b 5' CpG island hypermethylation has been described as one of the most frequent mechanisms leading to inactivation of these tumor suppressor genes in hematological malignancies. The p16 and p15 promoter regions were studied using methylation-specific polymerase chain reaction in 53 CD30 non-Hodgkin's lymphomas (25 anaplastic large-cell, 13 peripheral T cell, and 15 anaplastic diffuse large B cell) and 26 Hodgkin's lymphomas, with the aim of comparing the methylation status of these tumor suppressor genes in anaplastic large-cell lymphomas and other related entities. p16 and p15 methylation was detected, respectively, in 28% and 60% of CD30 non-Hodgkin's lymphomas and in 38% and 42% of Hodgkin's neoplasms. This confirms the p16-methylated status in Hodgkin's cases described in a single previous study and adds information concerning the p15 gene that was also found to be methylated in this lymphoma subtype. Methylation incidence within cases at diagnosis and at relapse suggests that it is an early event in anaplastic large-cell lymphomas, being involved in tumor progression in Hodgkin's cases. Our results show that although p16 and/or p15 methylation is involved in non-Hodgkin's and Hodgkin's tumors that share morphological and phenotypic features, differences in incidence, pattern of methylation, and implication in tumor progression are observed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12213729      PMCID: PMC3278767          DOI: 10.1016/S0002-9440(10)64261-7

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  33 in total

1.  Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies.

Authors:  J G Herman; C I Civin; J P Issa; M I Collector; S J Sharkis; S B Baylin
Journal:  Cancer Res       Date:  1997-03-01       Impact factor: 12.701

Review 2.  DNA methylation errors and cancer.

Authors:  P A Jones
Journal:  Cancer Res       Date:  1996-06-01       Impact factor: 12.701

3.  Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas.

Authors:  J Fueyo; C Gomez-Manzano; J M Bruner; Y Saito; B Zhang; W Zhang; V A Levin; W K Yung; A P Kyritsis
Journal:  Oncogene       Date:  1996-10-17       Impact factor: 9.867

4.  p15(INK4B) CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing.

Authors:  E E Cameron; S B Baylin; J G Herman
Journal:  Blood       Date:  1999-10-01       Impact factor: 22.113

5.  Hypermethylation of a 5' CpG island of p16 is a frequent event in non-Hodgkin's lymphoma.

Authors:  B Martinez-Delgado; J Fernandez-Piqueras; M J Garcia; E Arranz; J Gallego; C Rivas; M Robledo; J Benitez
Journal:  Leukemia       Date:  1997-03       Impact factor: 11.528

6.  Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.

Authors:  J G Herman; A Merlo; L Mao; R G Lapidus; J P Issa; N E Davidson; D Sidransky; S B Baylin
Journal:  Cancer Res       Date:  1995-10-15       Impact factor: 12.701

7.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.

Authors:  J G Herman; J R Graff; S Myöhänen; B D Nelkin; S B Baylin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

8.  Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression.

Authors:  J A Reed; F Loganzo; C R Shea; G J Walker; J F Flores; J M Glendening; J K Bogdany; M J Shiel; F G Haluska; J W Fountain
Journal:  Cancer Res       Date:  1995-07-01       Impact factor: 12.701

9.  Involvement of CDKN2 (p16INK4A/MTS1) and p15INK4B/MTS2 in human leukemias and lymphomas.

Authors:  T Otsuki; H M Clark; A Wellmann; E S Jaffe; M Raffeld
Journal:  Cancer Res       Date:  1995-04-01       Impact factor: 12.701

10.  CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2'deoxycytidine.

Authors:  G A Otterson; S N Khleif; W Chen; A B Coxon; F J Kaye
Journal:  Oncogene       Date:  1995-09-21       Impact factor: 9.867

View more
  16 in total

Review 1.  Epigenetic inactivation of tumor suppressor genes in hematologic malignancies.

Authors:  Tomohiro Kinoshita
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

Review 2.  Genomic alterations in Hodgkin's lymphoma.

Authors:  Marc A Weniger; Thomas F E Barth; Peter Möller
Journal:  Int J Hematol       Date:  2006-06       Impact factor: 2.490

3.  DNA methylation profiles in diffuse large B-cell lymphoma and their relationship to gene expression status.

Authors:  B L Pike; T C Greiner; X Wang; D D Weisenburger; Y-H Hsu; G Renaud; T G Wolfsberg; M Kim; D J Weisenberger; K D Siegmund; W Ye; S Groshen; R Mehrian-Shai; J Delabie; W C Chan; P W Laird; J G Hacia
Journal:  Leukemia       Date:  2008-02-21       Impact factor: 11.528

4.  Prognostic significance of epigenetic inactivation of p16, p15, MGMT and DAPK genes in follicular lymphoma.

Authors:  Milena Krajnović; Milica Radojković; Radoslav Davidović; Bogomir Dimitrijević; Koviljka Krtolica
Journal:  Med Oncol       Date:  2012-12-30       Impact factor: 3.064

5.  Hypermethylation of p15 gene in diffuse - large B-cell lymphoma: association with less aggressiveness of the disease.

Authors:  Milena Krajnović; Maja Peruničić Jovanović; Biljana Mihaljević; Boško Anđelić; Olivera Tarabar; Slavica Knežević-Ušaj; Koviljka Krtolica
Journal:  Clin Transl Sci       Date:  2014-05-09       Impact factor: 4.689

6.  DNA methylation patterns in EBV-positive and EBV-negative Hodgkin lymphomas.

Authors:  Myriam Ben Dhiab; Sonia Ziadi; Sarra Mestiri; Riadh Ben Gacem; Feryel Ksiaa; Mounir Trimeche
Journal:  Cell Oncol (Dordr)       Date:  2015-09-08       Impact factor: 6.730

7.  Epigenetic silencing of a proapoptotic cell adhesion molecule, the immunoglobulin superfamily member IGSF4, by promoter CpG methylation protects Hodgkin lymphoma cells from apoptosis.

Authors:  Paul G Murray; Yichao Fan; Gillian Davies; Jianming Ying; Hua Geng; Ka Man Ng; Hongyu Li; Zifen Gao; Wenbin Wei; Shikha Bose; Jennifer Anderton; Georgia Kapatai; Gary Reynolds; Akihiko Ito; Teresa Marafioti; Ciaran Bj Woodman; Richard Ambinder; Qian Tao
Journal:  Am J Pathol       Date:  2010-08-13       Impact factor: 4.307

8.  p15(INK4b) plays a crucial role in murine lymphoid development and tumorigenesis.

Authors:  Kwame Osei-Sarfo; Ignacio Perez de Castro; Angel Pellicer
Journal:  Carcinogenesis       Date:  2012-01-06       Impact factor: 4.944

9.  Downregulation of HO-1 promoted apoptosis induced by decitabine via increasing p15INK4B promoter demethylation in myelodysplastic syndrome.

Authors:  D Ma; Q Fang; P Wang; R Gao; J Sun; Y Li; X Y Hu; J S Wang
Journal:  Gene Ther       Date:  2015-02-05       Impact factor: 5.250

Review 10.  Nitric oxide: perspectives and emerging studies of a well known cytotoxin.

Authors:  William A Paradise; Benjamin J Vesper; Ajay Goel; Joshua D Waltonen; Kenneth W Altman; G Kenneth Haines; James A Radosevich
Journal:  Int J Mol Sci       Date:  2010-07-16       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.